BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)Business Wire • 05/04/22
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New JerseyBusiness Wire • 04/29/22
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström's MacroglobulinemiaBusiness Wire • 04/28/22
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual MeetingBusiness Wire • 04/27/22
Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell CarcinomaBusiness Wire • 04/27/22
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New JerseyBusiness Wire • 04/21/22
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary SeriesBusiness Wire • 04/19/22
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell CarcinomaBusiness Wire • 04/15/22
BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia StudyBenzinga • 04/11/22
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic LeukemiaBusiness Wire • 04/11/22
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022Business Wire • 04/08/22
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLCBusiness Wire • 04/06/22
Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting riskMarket Watch • 03/26/22
BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/17/22